← Back to Search

Monoclonal Antibodies

MCLA-145 for Non-Hodgkin's Lymphoma

Phase 1
Waitlist Available
Research Sponsored by Merus N.V.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial tests MCLA-145, a new drug, on patients with advanced or spreading cancers. It aims to find out if the drug is safe and effective in helping the immune system fight cancer.

Eligible Conditions
  • Cancer
  • Solid Tumors
  • Non-Hodgkin's Lymphoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

1Treatment groups
Experimental Treatment
Group I: MCLA-145Experimental Treatment1 Intervention
In Part 1, the dose escalation phase, patients with advanced or recurrent/metastatic solid tumors or B-cell lymphomas will receive escalating doses of MCLA-145 ( every 2 weeks ) until MTD or RDE is reached. In Part 2, the expansion phase, participants with advanced or metastatic solid tumors will receive intravenous infusion of MCLA-145 at the recommended phase II dose every 2 weeks. The duration of each treatment cycle is 28 days

Find a Location

Who is running the clinical trial?

Merus N.V.Lead Sponsor
9 Previous Clinical Trials
2,650 Total Patients Enrolled
Incyte CorporationIndustry Sponsor
382 Previous Clinical Trials
56,934 Total Patients Enrolled
Ernesto Wasserman, MDStudy DirectorMerus N.V.
3 Previous Clinical Trials
720 Total Patients Enrolled
~19 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top